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OBJECTIVE: To determine whether recombinant factor VIIa (rFVIIa) is associated with increased survival and/or
thromboembolic complications.
INTRODUCTION: Uncontrollable hemorrhage is the main cause of early mortality in trauma. rFVIIa has been
suggested for the management of refractory hemorrhage. However, there is conflicting evidence about the survival
benefit of rFVIIa in trauma. Furthermore, recent reports have raised concerns about increased thromboembolic
events with rFVIIa use.
METHODS: Consecutive massively transfused ($ 8 units of red blood cells within 12 h) trauma patients were studied.
Data on demographics, injury severity scores, baseline laboratory values and use of rFVIIa were collected. Rate of
transfusion in the first 6 h was used as surrogate for bleeding. Study outcomes included 24-hour and in-hospital
survival, and thromboembolic events. A multivariable logistic regression analysis was used to determine the impact
of rFVIIa on 24-hour and in-hospital survival.
RESULTS: Three-hundred and twenty-eight patients were massively transfused. Of these, 72 patients received rFVIIa.
As expected, patients administered rFVIIa had a greater degree of shock than the non-rFVIIa group. Using logistic
regression to adjust for predictors of death in the regression analysis, rFVIIa was a significant predictor of 24-hour
survival (odds ratio (OR)= 2.65; confidence interval 1.26–5.59; p=0.01) but not of in-hospital survival (OR=1.63;
confidence interval 0.79–3.37; p=0.19). No differences were seen in clinically relevant thromboembolic events.
CONCLUSIONS: Despite being associated with improved 24-hour survival, rFVIIa is not associated with a late survival
to discharge in massively transfused civilian trauma patients.
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INTRODUCTION
Hemorrhagic shock is a major cause of early in-hospital
death in trauma patients.
1 The severity of injury and shock
is associated with the degree of coagulopathy, which in turn
correlates with mortality.
2,3 The development of coagulo-
pathy in trauma is multifactorial; metabolic acidosis, core
hypothermia, consumption of clotting factors and dilutional
effects of resuscitation are the most important physiological
derangements involved in this process.
3 Early coagulopathy
initiated by tissue hypoperfusion that is independent of
dilution has been described.
2,4 The mainstay of prevention
and treatment of such challenging coagulopathy of trauma
includes rapid surgical cessation of bleeding; replenish-
ment of circulating blood volume with red blood cells
(RBCs); transfusion of coagulation factors and platelets by
blood component therapy; and correction of acidosis and
hypothermia.
5,6
Other strategies to deal with the coagulopathy of trauma
have been under investigation. Damage control resuscitation
has been described and advocates aggressive transfusion of
plasma and platelets in order to minimize the dilutional
effects of crystalloid and RBC transfusions.
7 More recently,
the use of pro-coagulant agents has also been investigated.
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is a pro-coagulant agent that has been evaluated for the
treatment of coagulopathy in trauma patients.
8,9 rFVIIa has
been licensed in many countries, including the United
States, Canada, European Union and Japan, for the treat-
ment of hemorrhagic events and for the prevention of
bleeding during surgical or invasive interventions in
patients with hemophilia A and B with inhibitors to coagu-
lation factors FVIII and IX; acquired hemophilia and con-
genital deficiency of coagulation factor VII.
10-12 In the
European Union and Japan, rFVIIa has also been licensed
for the treatment of Glanzmann’s thrombasthenia.
Following a case report published in 1999 on the
successful use of rFVIIa for major traumatic hemorrhage,
13
there has been increasing interest and use of rFVIIa to treat
coagulopathy and halt major bleeding in trauma patients. In
the military setting, rFVIIa is currently included in the
management of major hemorrhage.
14,15 However, there is
conflicting evidence in the literature on the use of the drug
outside approved indications.
16,17 Retrospective reports of a
small number of cases suggest beneficial effects of the drug
in controlling bleeding, reducing transfusion of blood
products and improving survival.
17,18 Two parallel, rando-
mized, placebo-controlled, double-blind clinical trials, per-
formed simultaneously to evaluate the safety and efficacy of
rFVIIa as an adjunct to control hemorrhage in trauma,
demonstrated a significant reduction in RBC transfusion in
blunt trauma.
19 In this study, not powered for mortality
endpoints, trends toward a reduction in mortality were
seen. Subsequently, a phase III randomized control trial,
stopped prematurely owing to unexpectedly low morta-
lity rates of the study patients, failed to demonstrate a
30-day survival benefit of rFVIIa use for bleeding trauma
patients.
20 Therefore, the potential benefit of rFVIIa in
trauma remains questionable. Furthermore, reports have
raised concerns about thromboembolic (TE) complications
associated with the use of rFVIIa in trauma.
21-23
We reviewed a large cohort of massively transfused
trauma patients to determine whether rFVIIa use was
associated with increased survival and/or clinically rele-
vant TE complications.
MATERIALS AND METHODS
The Trauma Registry and Blood Bank Database at
Sunnybrook Health Sciences Centre (SHSC), a Canadian
level I adult trauma center in Toronto, was used to identify a
retrospective cohort of all consecutive trauma patients
admitted between 1 January 2000 and 30 November 2006,
who received 8 or more units of RBCs within the first 12 h of
hospitalization. This inclusion criterion aimed to capture all
patients who were massively transfused early following
injury, and was similar to the inclusion criterion of another
randomized controlled trial on rFVIIa in trauma.
19 The
research ethics board at SHSC reviewed and approved the
study protocol.
The use of rFVIIa at SHSC has to be approved by a
transfusion medicine specialist as a salvage therapy when
all other interventions have failed. In the first 2 years of the
study (2000 and 2001), rFVIIa was administered at doses as
low as 17.1 mg/kg when trauma patients had received more
than 20 units of RBCs. As more experience was gained, and
after participation in the randomized clinical trial on rFVIIa
in trauma,
19 higher doses were used after fewer units of
RBC transfusion from 2002 until the end of the study period.
Of note, 5 patients treated with rFVIIa included in our
review were also part of the international trial on the drug.
19
After completion of the trial, the sponsoring company
confirmed that those 5 patients had received rFVIIa.
The Trauma Registry was used to obtain information on
patient demographics, including gender and age; mechan-
ism of injury; Injury Severity Score (ISS) and Abbreviated
Injury Scale Score (AIS), calculated after discharge or death
by the trauma registry staff; and hospital mortality. Manual
chart abstraction and electronic patient record retrieval were
conducted to gather data on 24-hour hospital mortality;
baseline laboratory values, including hemoglobin level,
platelet counts, arterial pH, base deficit, plasma lactate
levels, international normalized ratio and plasma fibrinogen
levels, were obtained. The electronic patient record was also
used to obtain information on TE events during the entire
hospital stay. It includes review of discharge or death notes
as well as radiology reports on Doppler ultrasound
examinations for deep venous thrombosis (DVT) and on
computed tomography angiogram scans for pulmonary
embolism.
Data on massively transfused trauma patients were
linked to the Blood Bank Information System (HCLL,
Mediware, New York, USA) to identify patients treated
with rFVIIa as part of their management for coagulopathy
within the first 24 h of hospitalization. The same blood bank
database was used to collect data on the time at which RBC
units were issued to the patients and the hospital chart was
reviewed to confirm their use. The rate of transfusion within
the first 6 h of hospital admission was calculated for all
included patients. This variable has been used as a
surrogate maker of the severity of bleeding and shown to
be a strong predictor of 24-hour in-hospital death in our
previous experience.
24
Outcomes
The main study outcomes were survival at 24 h and in-
hospital survival. Secondary outcomes included TE compli-
cations. Differences in TE complications (myocardial infarc-
tion, stroke, pulmonary embolism and DVT) during the
whole hospital stay were compared between rFVIIa-treated
and untreated patients.
Statistical Analysis
The administration of rFVIIa was the independent
variable. Other covariates analyzed include gender, age,
mechanism of injury, ISS, AIS for head injury, hemoglobin,
pH, base deficit, lactate, fibrinogen, international normal-
ized ratio and rate of RBC transfusion within 6 h of hospital
admission.
Univariate analysis was performed to assess differences
in demographics and baseline physiologic and injury
parameters. In order to determine whether rFVIIa use had
an impact on survival, we also performed a logistic
regression analysis, taking into consideration the major
potential predictors and known predictors of trauma
mortality. As for a previous analysis of a smaller sample
size, we fitted a multivariable logistic regression model to
assess for predictors of 24-hour and hospital survival.
24 A
discussion of the characteristics of the regression model can
be found in our previous work.
24 Variables considered for
analysis were initial pH value; platelet count; age; AIS for
head injury; rate of RBC transfusion and use of rFVIIa.
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25 head injury,
1 acidosis
26 and early coagulopathy
2 have
been shown to independently correlate with trauma
mortality. The final model included 6 variables for both
the 24-hour (119 deaths at 24 h) and in-hospital mortality
(161 inpatient deaths) analyses, respecting the recom-
mended rule of 1 variable for approximately 10 events.
In order to assess possible determinants of rFVIIa failure,
we performed a subgroup analysis accounting for baseline
characteristics, including age; injury severity score; degree
of shock and acidosis; coagulopathy and dose regimens
used between patients treated with rFVIIa who died and
survived within the first 24 h of hospitalization.
Descriptive statistics for continuous variables were pre-
sented as means and standard deviations or medians and
interquartile ranges, as appropriate, and as percentages for
the categorical variables. A t-test or Mann–Whitney U test
was used to compare the continuous variables and x
2 or
Fisher’s exact test to compare the categorical variables. The
analysis was performed using SAS 9.1 (SAS Institute Inc,
Cary, North Carolina, USA).
RESULTS
During the 6-year study period, 7076 trauma patients
were assessed by the Sunnybrook trauma team. Overall, 328
patients received $ 8 units of RBCs within 12 h of hospital
admission and were included in the study (Figure 1).
Among these massively transfused patients, 72 patients
were treated with rFVIIa.
The large majority of rFVIIa-treated patients (72%)
received only 1 dose of the medication, whereas 24% were
treated with 2 doses and only 4% had 3 doses of rFVIIa. The
time to administration of the first dose of rFVIIa from
hospital admission was 4.5 h (2.7–7.7). The time interval to
administration of a repeated dose was on average 2.3 h. A
median dose of 85.7 mg/kg (61.6–102.8) was initially admini-
stered. Because most patients received a single dose, the
median total dose was also 85.7 mg/kg (68.6–128.5).
Baseline characteristics of the rFVIIa and non-rFVIIa
groups are presented in Table 1. Of note, owing to the
critical clinical condition of this cohort of massively
transfused patients, laboratory tests were frequently not
done for many patients (Table 1). rFVIIa-treated patients
had higher lactate (9 ¡3.8 vs. 7 ¡3.4, p=0.02) and base
deficit (10 ¡6.6 vs. 7 ¡5.4, p=0.002), thus were more
acidotic than those who had not received rFVIIa. There were
no significant differences in the baseline coagulation profiles
of the two groups. rFVIIa patients were in more severe
hemorrhagic shock, requiring more RBCs in the first 24 h
after admission than non-rFVIIa patients (24.9 vs. 14.9 units
of RBCs, p=0.0001). Similarly, rFVIIa patients required a
greater rate of RBC transfusions than non-rFVIIa patients
(3.1 ¡1.7 vs. 2.1 ¡1.0, p,0.0001) during the initial resusci-
tation period (before administering rFVIIa to those who
received the drug and during the first 6 h for those who did
not receive rFVIIa; Table 1).
On univariate analysis, the administration of rFVIIa did
not appear to offer any survival advantage to trauma
patients; either for 24-hour survival (66.7% in rFVIIa group
vs. 62.9% in the non-rFVIIa group, p=0.56) or for overall
survival (48.6% vs. 51.6%, p=0.66). As in a previous
analysis conducted in a smaller cohort of our patients,
24
using multivariable logistic regression analysis to adjust for
differences in baseline characteristics between the rFVIIa
and non-rFVIIa groups, we evaluated independent predic-
tors of 24-hour and in-hospital survival. rFVIIa was shown
to be associated with a significant improvement in 24-hour
survival (odds ratio (OR)=2.65; 95% CI 1.26-5.59; p=0.01).
Figure 1 - Study protocol. RBC = red blood cells; rFVIIa, recombinant factor VIIa.
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survival (OR=1.63; CI 0.79-3.37; p=0.19). Initially lower pH
and platelet count; older age; worse head AIS and higher
transfusion rates were all significant predictors of 24-hour
and in-hospital survival (Table 2).
Subgroup analysis of patients treated with rFVIIa
revealed that patients who died within 24 h of hospitaliza-
tion were more acidotic, being transfused at higher rates,
and had lower platelet counts (Table 3). They received the
first rFVIIa dose earlier (time to rFVIIa from admission) than
the patients who were alive at 24 h (3.5 (2.1-5.1) vs. 5.25 (3.2-
9.1), p=0.0089). There were no statistically significant
differences with respect to age, ISS, severity of head injury,
number of doses and total dosage of rFVIIa administered
(Table 3).
Seven patients (9.7%) in the rFVIIa group and 16 (6.2%) in
the group of massively transfused patients not treated with
rFVIIa had TE events, including myocardial infarction,
stroke, pulmonary embolism and DVTs. This difference did
not reach statistical significance (p=0.3).
DISCUSSION
rFVIIa has been studied for the treatment of clinical
conditions apart from hemophilia and other congenital
coagulopathies and its use has expanded considerably over
the past decade.
10,16,27 Owing to its systemic administration
by an intravenous route and mechanism of action—namely,
acting at the site of injury where it binds to exposed tissue
factor enhancing thrombin generation on activated platelets,
and therefore promoting coagulopathy, rFVIIa seems to be
an appealing option for the treatment of coagulopathy
following trauma. However, this review was unable to
document in-hospital survival benefit of the use of rFVIIa in
a multivariable logistic regression analysis of massively
bleeding trauma patients. Thorough discussion of the
limitations of the regression model can be found in our
previous work.
24 The use of rFVIIa was not associated with
an increased rate of TE events in this cohort of patients.
The effect of early administration of rFVIIa in a setting of
combat casualties was recently reviewed and found to be
associated with decreased 30-day mortality.
28 In our study,
we were unable to demonstrate late survival benefit of the
use of rFVIIa. There are several hypotheses that might
account for these different findings. First, in the military
setting, rFVIIa has been used earlier in the management of
bleeding after transfusion of 4–6 RBCs and at larger doses.
In contrast, our median time to rFVIIa administration was
4.5 h and the median total dose was 86 mg/kg compared
with a 120 mg/kg of the drug given at a median of 2 h from
admission in the military setting.
28 Second, the military
study population included mostly soldiers with penetra-
ting injuries and lower rates of head injuries, for which
timely surgical intervention for surgical bleeding is the
major determinant of outcomes. Finally, as mentioned in the
discussion section of the study,
28 there are limitations of
data gathered in a war zone, particularly missing variables
owing to the complexity of collecting data from military
patients and co-interventions.
In the civilian setting, two randomized controlled trials
were unable to document a survival advantage, despite
superior study design and greater power.
19,20 The early
mortality rates of patients in both studies were ,20% (all
four arms), whereas the 24-hour mortality rate of our cohort
was about 35%, probably owing to selection bias from our
Table 1 - Demographics and baseline characteristics.
Characteristics
rFVIIa
(n=72)
Non-rFVIIa
(n=256) p-Value
Male n (%) 48 (67) 185 (72.3) 0.35
Age (years) 34 (23-48)
* 35 (22-52)
* 0.8854
ISS 43 (¡15) 41 (¡15) 0.2971
Head AIS 2 (0-5)
* 3 (0-5)
* 0.0765
Penetrating n (%) 33 (31) 57 (22) 0.1461
Hemoglobin (g/L) 98 (¡27) 101 (¡23) 0.3888
Platelet count (610
4) 169 (¡99) 192 (¡95) 0.0854
ipH{ 7.20 (¡0.18) 7.26 (¡0.17) 0.0266
Base deficit{ 10 (¡6.6) 7 (¡5.4) 0.0018
Lactate1 (mmol/L) 9 (¡3.8) 7 (¡3.4) 0.0166
Fibrinogen" (g/L) 0.86 (¡0.5) 0.93 (¡0.5) 0.4100
INR** 1.4 (1.2-1.9)
* 1.3 (1.2-1.7)
* 0.0665
Transfusion rate
(RBC units/h)
3.1 (¡1.7) 2.1 (¡1.0) ,0.0001
Mean (¡ standard deviation) and t-test used.
*Medians and IQR are reported and Mann–Whitney U test used; x
2 or
Fisher’s exact test used for categorical variables.
{12 missing in the control group and 1 in the rFVIIa group.
{109 missing in the control group and 4 in the rFVIIa group.
1160 missing in the control group and 36 missing in the rFVIIa group.
"163 missing in the control group and 20 missing in the rFVIIa group.
**16 missing in the control group and none missing in the rFVIIa group.
AIS = Abbreviated Injury Scale Score; INR = international normalized
ratio; ipH = initial pH; ISS = Injury Severity Score; RBC = red blood cells;
rFVIIa, recombinant factor VIIa.
Table 2 - Independent predictors of 24-hour and in-hospital survival.
24-Hour survival* Hospital survival{
Predictors OR (95% CI) p-Value OR (95% CI) p-Value
rFVIIa 2.65 (1.26-5.59) 0.0106 1.63 (0.79-3.37) 0.1883
ipH (0.1 increase) 1.26 (1.06-1.49) 0.0082 1.39 (1.15-1.68) 0.0005
Platelet count (100 increase) 1.51 (1.06-1.49) 0.0130 1.49 (1.09-2.04) 0.0128
Age 0.98 (0.97-0.99) 0.0130 0.97 (0.96-0.99) 0.0003
Transfusion 0.51 (0.40-0.66) ,0.0001 0.47 (0.35-0.62) ,0.0001
Head AIS 0.84 (0.74-0.96) 0.0087 0.69 (0.60-0.80) ,0.0001
*Hosmer–Lemeshow goodness-of-fit p=0.0865 suggesting a potential lack-of-fit. We therefore investigated deviance influence statistics against predicted
values and we detected potentially influential points. We refitted the model without those points and the results did not change qualitatively therefore
we present the model with the complete data. The c-statistic for this model is 0.79.
{Hosmer–Lemeshow goodness-of-fit p=0.9184 and the c-statistic=0.83.
AIS = Abbreviated Injury Scale Score; CI = confidence interval; ipH = initial pH; OR = odds ratio; rFVIIa = recombinant factor VIIa.
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104use of rFVIIa as a final desperate attempt. The recently
published phase III trial experienced the same unexpectedly
low mortality rates of the study population, which led to its
premature termination based on a futility analysis and thus
failure to demonstrate any survival advantage of rFVIIa
use in trauma.
20 In both trials, blunt trauma patients who
received rFVIIa had a lower ISS (33¡13 in Boffard et al.
19
and 32.8¡11.3 in Hauser et al.
20) than our cohort of rFVIIa-
treated patients (43¡15). Because our study patients were in
more severe hemorrhagic shock, survival differences may
have been accentuated in the first 24 h of hospitalization.
Unlike some combat settings, massive transfusion proto-
cols in civilian settings usually have rFVIIa available only to
trauma patients on compassionate grounds for refractory
bleeding unresponsive to surgical and component therapy.
Therefore, a possible selection bias might exist in retro-
spective studies attempting to determine the efficacy of
rFVIIa in this setting. In our study, most rFVIIa patients
were more acidotic on hospital arrival and required a
greater rate of RBC transfusions in the first 6 h than non-
rFVIIa patients. By identifying a large cohort of massively
bleeding trauma patients, we were able to adjust for some of
these imbalances to demonstrate a possible association with
improvement in early mortality by administering rFVIIa. As
rFVIIa was primarily expected to affect the mortality of
patients who would otherwise have died from hemorrhage,
measuring early in-hospital survival was a reasonable
primary outcome for this study. Of note, rFVIIa patients
who survived were more likely to have higher platelet
counts, less acidemia and lower base deficits at baseline
than rFVIIa patients who were dead at 24 h. Three
interpretations are possible, one is that rFVIIa was started
too late in patients who died, when physiological derange-
ments were irreversible; another is that patients who
survived had their thrombocytopenia and acidosis better
corrected; the last is that the patients who died were
bleeding more quickly and more severely injured than those
who survived. The last explanation is the most likely,
especially because the transfusion rate was greater in the
rFVIIa patients who died than in those who survived.
Therefore, the major practical point in administering rFVIIa
remains that surgical control of bleeding has primacy and
that if rFVIIa has any role it is as an adjunct for hemorrhage
control. A secondary point is that correcting acidosis may
increase the efficacy of rFVIIa. Animal data have shown that
rFVIIa activity is dramatically reduced at pH levels of
#7.2.
29 Clinical guidelines have suggested correction of
arterial pH to levels of $7.2 for appropriate use of rFVIIa.
30
We had lower rates of TE complications for this cohort of
severely injured and massively transfused trauma patients
than found by others (rFVIIa group: 9.7%; non-rFVIIa group:
6.2% vs. approximately 20% in the literature).
20,31,32 This
lower frequency might be due to the retrospective nature of
the surveillance, where non-clinically significant TE events
might not have been captured; the existence in our
institution of a dedicated thromboembolism team that
follows up all trauma patients daily from day 1 of admission
and oversees the management of DVT prophylaxis; and the
low incidence of arterial injuries, which has been associated
with increased risk of TE events following rFVIIa use.
22
Limitations
Owing to the retrospective nature of this study, numerous
limitations must be considered. First, the study was
conducted over a period of 6 years when the use of the drug
evolved considerably. At the onset of use of rFVIIa at our
institution, doses as low as 17 mg/kg were administered as a
last resort therapy. It was not possible to account for these
changes in practice over the time of the study. Second, there
may be a survivorship bias against patients receiving lower
doses of rFVIIa as they might have had early deaths
preventing administration of additional doses of the drug.
However,a large majority(72%) of patientswere treated with
a single dose of the drug regardless of outcome andsurvivors
who received additional doses were bleeding and probably
in a more severe condition at the time of further doses. Third,
despite no statistically significant difference in head AIS
between rFVIIa and non-rFVIIa groups, we cannot totally
exclude the possibility of mortality differences due to severe
head injuries within the first 24 h. However, we adjusted for
head AIS in our regression model. Fourth, we did not have
information on all comorbidities available to account for
potential differences between groups. Fifth, data for all
critical laboratory tests were not collected in many cases, an
inherent challenge when studying severely injured patients
with a high early mortality rate. Finally, owing to the
retrospective nature of the study, there was no set screening
protocol for prospective identification of TE events.
CONCLUSIONS
In the context of massively transfused trauma patients,
although the use of rFVIIa to correct coagulopathy was
associated with a twofold improvement in survival rates at
24 h, this did not translate into an improvement in survival
to hospital discharge.
The survival benefit of rFVIIa seen in this analysis may be
underestimated owing to selection bias, as more severely
injured patients received rFVIIa. Alternatively, patients with
severe hemorrhage and non-salvageable injuries may have
been more likely to receive rFVIIa, assisting survival to 24 h
only to experience late non-hemorrhagic deaths after arrival
at the intensive care unit. The benefit of rFVIIa use in
trauma remains highly questionable given the unfavourable
results of two randomized trials and this analysis of a large
cohort of civilian trauma patients.
Table 3 - Subgroup analysis of patients receiving rFVIIa.
Characteristics
rFVIIa Alive at
24 h (n=48)
rFVIIa Dead at
24 h (n=24) p-Value
Age 38 (¡16) 38 (¡20) 0.96
ISS 44 (¡14) 42 (¡16) 0.49
Head AIS* 2 (0-5)* 0.5 (0-5)* 0.42
Hemoglobin (g/L) 101 (¡30) 92 (¡23) 0.22
Platelet count (610
4) 190 (¡101) 127 (¡81) 0.0096
ipH 7.3 (¡0.1) 7.1 (¡0.2) 0.0002
Base deficit 8.0 (¡5.3) 14 (¡7.3) 0.0004
Fibrinogen (g/L) 0.89 (¡0.5) 0.79 (¡0.4) 0.50
INR* 1.34 (1.2-1.9)* 1.51 (1.3-1.9)* 0.06
Doses N (%)
1 32 (66.7) 20 (83.3)
2 14 (29.2) 3 (12.5) 0.22
3 2 (4.2) 1 (4.2)
Time to first dose* (h) 5.25 (3.2-9.1) 3.5 (2.1-5.1) 0.0089
Total dosage* 89 (80-147)* 71.3 (65-118)* 0.08
Transfusion rate
pre-rFVIIa (RBC units/h)
2.7 (¡1.6) 4 (¡1.7) 0.002
Mean (¡ standard deviation) and t-test used.
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